CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted…
EMERYVILLE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop…
THE WOODLANDS, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its first quarter 2024…
Libervant is the first and only FDA approved orally administered rescue product for the treatment of seizure clusters in patients…
VANCOUVER, British Columbia, April 26, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed…
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, April 26,…
Conversion of promissory notes into common stock removed $94.9 million in pro forma balance sheet liabilities.The converted common stock is…
Shareholders approved all proposals by a large majorityGENEVA, SWITZERLAND / ACCESSWIRE / April 26, 2024 / RELIEF THERAPEUTICS Holding SA…
LARGO, FL / ACCESSWIRE / April 26, 2024 / PharmaLink Inc., a national leader in pharmaceutical reverse distribution, and Recall…
April 26, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready…